SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022244154> ?p ?o ?g. }

Showing items 1 to 79 of 79 with 100 items per page.

W2022244154 endingPage "23711" @default.
W2022244154 startingPage "23707" @default.
W2022244154 abstract "Upregulation of key components of the 2′,5′-oligoadenylate (2–5A) synthetase/RNase L pathway have been identified in extracts of peripheral blood mononuclear cells from individuals with chronic syndrome, including the presence of a low molecular weight form of RNase L. In this study, analysis of 2′,5′-Oligoadenylate (2–5A) binding and activation of the 80- and 37-kDa forms of RNase L has been completed utilizing photolabeling/immunoprecipitation and affinity assays, respectively. Saturation of photolabeling of the 80- and the 37-kDa RNase L with the 2–5A azido photoprobe, [32P]pApAp(8-azidoA), was achieved. Half-maximal photoinsertion of [32P]pApAp(8-azidoA) occurred at 3.7 × 10−8m for the 80-kDa RNase L and at 6.3 × 10−8m for the 37-kDa RNase L. Competition experiments using 100-fold excess unlabeled 2–5A photoaffinity probe, pApAp(8-azidoA), and authentic 2–5A (p3A3) resulted in complete protection against photolabeling, demonstrating that [32P]pApAp(8-azidoA) binds specifically to the 2–5A-binding site of the 80- and 37-kDa RNase L. The rate of RNA hydrolysis by the 37-kDa RNase L was three times faster than the 80-kDa RNase L. The data obtained from these 2–5A binding and 2–5A-dependent activation studies demonstrate the utility of [32P]pApAp(8-azidoA) for the detection of the 37-kDa RNase L in peripheral blood mononuclear cell extracts. Upregulation of key components of the 2′,5′-oligoadenylate (2–5A) synthetase/RNase L pathway have been identified in extracts of peripheral blood mononuclear cells from individuals with chronic syndrome, including the presence of a low molecular weight form of RNase L. In this study, analysis of 2′,5′-Oligoadenylate (2–5A) binding and activation of the 80- and 37-kDa forms of RNase L has been completed utilizing photolabeling/immunoprecipitation and affinity assays, respectively. Saturation of photolabeling of the 80- and the 37-kDa RNase L with the 2–5A azido photoprobe, [32P]pApAp(8-azidoA), was achieved. Half-maximal photoinsertion of [32P]pApAp(8-azidoA) occurred at 3.7 × 10−8m for the 80-kDa RNase L and at 6.3 × 10−8m for the 37-kDa RNase L. Competition experiments using 100-fold excess unlabeled 2–5A photoaffinity probe, pApAp(8-azidoA), and authentic 2–5A (p3A3) resulted in complete protection against photolabeling, demonstrating that [32P]pApAp(8-azidoA) binds specifically to the 2–5A-binding site of the 80- and 37-kDa RNase L. The rate of RNA hydrolysis by the 37-kDa RNase L was three times faster than the 80-kDa RNase L. The data obtained from these 2–5A binding and 2–5A-dependent activation studies demonstrate the utility of [32P]pApAp(8-azidoA) for the detection of the 37-kDa RNase L in peripheral blood mononuclear cell extracts. adenylyl-(2′ → 5′)-adenylyl- (2′ → 5′)-adenylyl-(2′ → 5′)-adenosine polyacrylamide gel electrophoresis 5′-O-triphosphoryl-adenylyl-(2′ → 5′)-adenylyl-(2′ → 5′)-adenosine polycytidylic acid (5′) 5′-O-triphosphoryl-8-azidoadenylyl-(2′ → 5′)8-azidoadenylyl-(2′ → 5′)8-azidoadenosine chronic fatigue syndrome peripheral blood mononuclear cell. All other abbreviations used were as described in Ref. 1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar Previous studies from this laboratory (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar) described structural similarities between two forms of 2′,5′-oligoadenylate (2–5A)1-dependent RNase L in extracts of peripheral blood mononuclear cells (PBMC). The 2–5A-dependent 80-kDa RNase L is the terminal enzyme in the 2–5A synthetase/RNase L antiviral defense pathway (2Stark G.R. Kerr I.M. Williams B.R. Silverman R.H. Scheiber R.D. Annu. Rev. Biochem. 1998; 67: 227-264Crossref PubMed Scopus (3365) Google Scholar). RNase L is distinguished from other RNases in that it requires 2–5A for allosteric activation (reviewed in Refs. 1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar and 3Sen G.C. Lengyel P. J. Biol. Chem. 1992; 267: 5017-5020Abstract Full Text PDF PubMed Google Scholar, 4Sen G.C. Ransohoff R.M. Adv. Virus Res. 1993; 42: 57-102Crossref PubMed Scopus (309) Google Scholar, 5Rebouillat D. Hovanessian A.G. J. Interferon Cytokine Res. 1999; 19: 295-308Crossref PubMed Scopus (180) Google Scholar, 6Justesen J. Hartmann R. Kjeldgaard N.O. Cell. Mol. Life Sci. 2000; 57: 1593-1612Crossref PubMed Scopus (173) Google Scholar). The 80-kDa RNase L plays an essential role in the inhibition of viral mRNA and thus the inhibition of viral protein synthesis (3Sen G.C. Lengyel P. J. Biol. Chem. 1992; 267: 5017-5020Abstract Full Text PDF PubMed Google Scholar, 4Sen G.C. Ransohoff R.M. Adv. Virus Res. 1993; 42: 57-102Crossref PubMed Scopus (309) Google Scholar). In addition to the 80-kDa form of RNase L, a 40/42-kDa form has been identified and is thought to be a proteolytic degradation product of the 80-kDa RNase L (7Bayard B. Bette-Bobillo P. Aliau S. Eur. J. Biochem. 1994; 223: 403-410Crossref PubMed Scopus (5) Google Scholar, 8Bisbal C. Salehzada T. Lebleu B. Bayard B. Eur. J. Biochem. 1989; 179: 595-602Crossref PubMed Scopus (38) Google Scholar). As part of ongoing studies on the up-regulation of the 2–5OAS/RNase L antiviral pathway, a previously unknown 37-kDa form of RNase L has recently been identified in extracts of PBMC from individuals who met the diagnostic criteria for chronic fatigue syndrome (CFS) (9Shetzline S. E Martinand-Mari C Herst C. V Englebienne P De Meirleir K Peterson D. L Suhadolnik R. J Shetzline S. E Martinand-Mari C Herst C. V Englebienne P De Meirleir K Peterson D. L Suhadolnik R. J American Association for Chronic Fatigue Syndrome Fifth International Research Conference. abstract 95, Seattle, WAJanuary-2001: 26-29Google Scholar, 10Suhadolnik R.J. Peterson D.L. Cheney P.R. Horvath S.E. Reichenbach N.L. O'Brien K. Lombardi V. Welsh S. Furr E.G. Charubala R. Pfleiderer W. J. Chronic Fatigue Syndrome. 1999; 5: 223-242Crossref Scopus (31) Google Scholar, 11Holmes G.P. Kaplan J.E. Glantz N.M. Komaroff A.L. Schonberger L.B. Straus S.E. Jones J.F. Dubois R.E. Cunningham-Rundles C. Pahwa S. Tosato G. Zegano L.S. Purtilo D.T. Brown N. Schooley R.T. Bris I. Ann. Intern. Med. 1988; 108: 387-389Crossref PubMed Scopus (1419) Google Scholar, 12Fukuda K. Straus S.E. Hickie I. Sharpe M.C. Dobbins J.G. Komaroff A.L. Ann. Intern. Med. 1994; 121: 953-959Crossref PubMed Scopus (4150) Google Scholar). We had previously demonstrated that the 2–5OAS/RNase L pathway is constitutively active in PBMC extracts from individuals with CFS; 2–5OAS is predominantly in its activated form and levels of bioactive 2–5A and RNase L enzyme activity are elevated in CFS PBMC extracts compared with healthy control PBMC extracts (13Suhadolnik R.J. Reichenbach N.L. Hitzges P. Sobol R.W. Peterson D.L. Henry B. Ablashi D.V. Müller W.E.G. Schröder H.C. Carter W.A. Strayer D.R. Clin. Infect. Dis. 1994; 18: S96-S104Crossref PubMed Scopus (117) Google Scholar, 14Suhadolnik R.J. Reichenbach N.L. Hitzges P. Adelson M.E. Peterson D.L. Cheney P.R. Salvato P. Thompson C. Loveless M. Müller W.E.G. Schröder H.C. Strayer D.R. Carter W.A. In Vivo. 1994; 8: 599-604PubMed Google Scholar). Continued analyses of CFS PBMC extracts have revealed the presence of a novel low molecular mass RNase L that binds 2–5A, exhibits 2–5A-dependent RNase L activity, and has a molecular mass of 37-kDa under denaturing conditions (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar, 10Suhadolnik R.J. Peterson D.L. Cheney P.R. Horvath S.E. Reichenbach N.L. O'Brien K. Lombardi V. Welsh S. Furr E.G. Charubala R. Pfleiderer W. J. Chronic Fatigue Syndrome. 1999; 5: 223-242Crossref Scopus (31) Google Scholar). The 37-kDa RNase L has not been observed in PBMC extracts from individuals diagnosed with fibromyalgia or depression (15De Meirleir K. Bisbal C. Campine I. De Becker P. Salehzada T. Demettre E. Lebleu B. Am. J. Med. 2000; 108: 99-105Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar). Two subsets of individuals with CFS have been identified in PBMC extracts using azido photoaffinity labeling with [32P]pApAp(8-azidoA) and immunoprecipitation with a polyclonal antibody specific to the human 80-kDa RNase L (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar, 10Suhadolnik R.J. Peterson D.L. Cheney P.R. Horvath S.E. Reichenbach N.L. O'Brien K. Lombardi V. Welsh S. Furr E.G. Charubala R. Pfleiderer W. J. Chronic Fatigue Syndrome. 1999; 5: 223-242Crossref Scopus (31) Google Scholar). One subset contains only the 37-kDa RNase L and the second subset contains both the 80- and 37-kDa RNase L. The subset of CFS PBMC containing only the 37-kDa RNase L had the higher level of RNase L activity compared with the subset containing both the 80- and 37-kDa forms of RNase L (2Stark G.R. Kerr I.M. Williams B.R. Silverman R.H. Scheiber R.D. Annu. Rev. Biochem. 1998; 67: 227-264Crossref PubMed Scopus (3365) Google Scholar). In a two-site randomized-coded study, the presence of the 37-kDa RNase L also correlated with the level of clinical disability experienced by the study subjects (10Suhadolnik R.J. Peterson D.L. Cheney P.R. Horvath S.E. Reichenbach N.L. O'Brien K. Lombardi V. Welsh S. Furr E.G. Charubala R. Pfleiderer W. J. Chronic Fatigue Syndrome. 1999; 5: 223-242Crossref Scopus (31) Google Scholar). The elucidation of the molecular structure of the 37-kDa RNase L has been a major effort in this laboratory (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar). We hypothesized that the observed differences in the levels of biologically active 2–5A and RNase L activity in healthy control and CFS PBMC extracts could be attributed to differences in the 2–5A binding affinity or enzyme activity of the 80- and 37-kDa forms of RNase L. In the current study, we have characterized the 2–5A binding and activation of the 80- and 37-kDa RNase L in healthy control and CFS PBMC extracts utilizing azido photochemical cross-linking and affinity binding assays. Saturation of 2–5A azido photolabeling was achieved for the 80- and 37-kDa forms of RNase L. Competition experiments revealed that the 2–5A azido photoaffinity probe, [32P]pApAp(8-azidoA), binds specifically to the 80- and 37-kDa RNase L in healthy control and CFS PBMC extracts, respectively. The rate of RNA hydrolysis by the 37-kDa RNase L was three time faster than the 80-kDa RNase L. The data presented in this study also demonstrate the use of the 2–5A azido photoprobe for the detection of the 37-kDa RNase L in CFS PBMC extracts. The 2–5A azido photoaffinity probe, ApAp(8-azidoA), and 2–5A4 were generously supplied by Dr. Wolfgang Pfleiderer (Konstanz Universität, Konstanz, Germany). The fibrous cellulose powder CF11 used to prepare the core(2–5A)-cellulose was from Whatman. Healthy control and CFS PBMC extracts were used as source of the 80- and 37-kDa RNase L, respectively. PBMC extracts were prepared in the presence of protease inhibitors as described previously (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar). All other materials were as described previously from this laboratory (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar). The chemical synthesis of ApAp(8-azidoA) was completed as described (16Charubala R. Pfleiderer W. Sobol R.W. Li S.W. Suhadolnik R.J. Helv. Chim. Acta. 1989; 72: 1354-1361Crossref Scopus (19) Google Scholar). Phosphorylation of the 5′ terminus of ApAp(8-azidoA) (0.15 mm) was performed with [γ-32P]ATP (6000 Ci/mmol) in the absence and presence of ATP (1.6 mm) and T4 polynucleotide kinase according to the manufacturer's directions. The yield of the radiolabel incorporation for [32P]pApAp (8-azidoA) in the absence of ATP was 30% with a specific activity of 6000 Ci/mmol and 5–10% in the presence of ATP with a specific activity of 60 Ci/mmol. Covalent photoaffinity labeling, immunoprecipitation, and quantitation of the 2–5A binding immunoreactive proteins from healthy control and CFS PBMC extracts were as described previously (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar). A concentration range of 0 to 700 nm[32P]pApAp(8-azidoA) (6 × 104 Ci/mol) was used to photolabel and immunoprecipitate 2–5A binding, immunoreactive proteins in PBMC extracts from healthy controls and CFS patients (50 μg of total protein) was described previously (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar). Covalent cross-linking of the 2–5A photoaffinity probe [32P]pApAp(8-azidoA) to the 80- and 37-kDa forms of RNase L was quantitated using a Fuji BAS 2000 PhosphorImager and converted to concentration of bound [32P]pApAp(8-azidoA) (nm) following photolabeling/immunoprecipitation experiments. The amount of bound [32P]pApAp(8-azidoA) was plotted as a function of the concentration of [32P]pApAp(8-azidoA) (nm) used per assay and fit to a nonlinear regression for one-site and two-site models using Sigma plot version 5.0 (17Chavan A.J. Nemoto Y. Narumiya S. Kozaki S. Haley B.E. J. Biol. Chem. 1992; 267: 14866-14870Abstract Full Text PDF PubMed Google Scholar, 18Shoemaker M.T. Haley B.E. Biochemistry. 1993; 32: 1883-1890Crossref PubMed Scopus (39) Google Scholar, 19Olcott M.C. Bradley M.L. Haley B.E. Biochemistry. 1994; 33: 11935-11941Crossref PubMed Scopus (35) Google Scholar). The specificity of [32P]pApAp(8-azidoA) binding to RNase L in PBMC extracts was determined by two types of competition experiments using unlabeled pApAp(8-azidoA) and p3A3. In the first type of competition experiment, PBMC extracts (50 μg of total protein) were combined with a mixture of radiolabeled [32P]pApAp(8-azidoA) (1 × 10−8m; 6 × 106 Ci/mol; 10,000 dpm) and varying concentrations of unlabeled pApAp(8-azidoA) (0 to 5 × 10−6m) and incubated for 30 min at 0 °C. In the second type of competition experiment, PBMC extracts (50 μg of total protein) were combined with a mixture of [32P]pApAp(8-azidoA) (1 × 10−8m; 6 × 106 Ci/mol; 60,000 dpm) and p3A3 (1 × 10−11 to 1 × 10−7m) and incubated for 30 min at 0 °C. The photolabeling mixtures were photolyzed, immunoprecipitated with a polyclonal antibody to human 80-kDa RNase L, fractionated by 10% SDS-PAGE, and analyzed as described from this laboratory (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar). The percent bound [32P]pApAp(8-azidoA) was plotted as a function of the concentration of unlabeled pApAp(8-azidoA) or p3A3 using Sigma plot 5.0. Core(2–5A)-cellulose assays were used to determine the activation of RNase L in PBMC extracts from healthy controls and CFS patients as described (20Silverman R.H. Anal. Biochem. 1985; 144: 450-460Crossref PubMed Scopus (48) Google Scholar, 21Suhadolnik R.J. Kariko K. Sobol R.W. Li S.W. Reichenbach N.L. Haley B.E. Biochemistry. 1988; 27: 8840-8846Crossref PubMed Scopus (14) Google Scholar). Briefly, in time-dependent activation assays, PBMC extracts (150 μg of total protein) were incubated with core(2–5A)-cellulose (0 °C, 1 h) to immobilize 80- and 37-kDa RNase L. The immobilized RNase L was combined with radiolabeled substrate, poly(U)-3′-[32P]pCp (1.1 × 10−5m; 10,000 dpm), and 2–5A activator, pA4 (1 × 10−7m), and incubated at 30 °C for 0 to 120 min (30 μl total reaction volume). The poly(U)-3′-[32P]pCp was precipitated and quantitated by scintillation spectrometry as described (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar). Non-2–5A-dependent RNase activity in PBMC extracts was determined in the presence of poly(C)-3′-[32P]pCp, which is not a substrate for RNase L (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar). The data were plotted as the percent RNA remaining as a function of the time of incubation at 30 °C using Sigma plot 5.0. Half-maximal (50%) hydrolysis of poly(U)-3′-[32P]pCp was determined as the midpoint between 100% RNA remaining and the amount of RNA remaining once maximal RNase L activity was attained. In the current study, we utilized the methods of covalent photoaffinity labeling with the 2–5A azido photoprobe, [32P]pApAp(8-azidoA), and immunoprecipitation with a polyclonal antibody to human RNase L to determine the binding requirements for the interaction of 2–5A with 80- and 37-kDa RNase L in healthy control and CFS PBMC extracts, respectively. By using cell extracts prepared from PBMC, we have chosen to employ a system that contains all the components necessary to form the activated complexes for the 80- and 37-kDa RNase L proteins (22Potter R.L. Haley B.E. Methods Enzymol. 1983; 91: 613-633Crossref PubMed Scopus (94) Google Scholar). In previous photolabeling studies, we have used 2–5A azido photoprobes to specifically identify the different forms of RNase L in interferon-treated L929 cell extracts (21Suhadolnik R.J. Kariko K. Sobol R.W. Li S.W. Reichenbach N.L. Haley B.E. Biochemistry. 1988; 27: 8840-8846Crossref PubMed Scopus (14) Google Scholar). We have also demonstrated that the activation of the 80-kDa RNase L in interferon-treated L929 cells extracts by an 8-azido-2–5A photoaffinity probe was comparable to the RNase L activity measured in the presence of p3A3 using core (2–5A)-cellulose assays (16Charubala R. Pfleiderer W. Sobol R.W. Li S.W. Suhadolnik R.J. Helv. Chim. Acta. 1989; 72: 1354-1361Crossref Scopus (19) Google Scholar, 21Suhadolnik R.J. Kariko K. Sobol R.W. Li S.W. Reichenbach N.L. Haley B.E. Biochemistry. 1988; 27: 8840-8846Crossref PubMed Scopus (14) Google Scholar). Core (2–5A)-cellulose assays were employed in the current study to determine 2–5A-dependent RNase activity in healthy control and CFS PBMC extracts. We have demonstrated that the expression of the 37-kDa RNase L in CFS PBMC extracts correlates with elevated levels of bioactive 2–5A and RNase L activity (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar, 10Suhadolnik R.J. Peterson D.L. Cheney P.R. Horvath S.E. Reichenbach N.L. O'Brien K. Lombardi V. Welsh S. Furr E.G. Charubala R. Pfleiderer W. J. Chronic Fatigue Syndrome. 1999; 5: 223-242Crossref Scopus (31) Google Scholar). Using the combined methods of covalent photoaffinity labeling with the 2–5A photoaffinity probe, [32P]pApAp(8-azidoA), and immunoprecipitation with a polyclonal antibody to human 80-kDa RNase L, the binding affinity of 2–5A to 80-kDa RNase L in healthy control PBMC extracts and to 37-kDa RNase L in CFS PBMC extracts was determined (Fig.1). The healthy control PBMC extracts chosen for the study contained only the 80-kDa RNase L and the CFS PBMC extracts contained only the 37-kDa RNase L. Binding of [32P]pApAp(8-azidoA) to either 80- or 37-kDa RNase L in PBMC extracts reached equilibrium in 30 min at 0 °C and remained constant through 90 min prior to photolabeling/immunoprecipitation (data not shown). The extent of photolabeling at 0 °C of the 80- and 37-kDa RNase L by [32P]pApAp(8-azidoA) reached a maximum at 60 s and remained constant through 90 s (data not shown). Therefore, photolysis was conducted for 60 s to maximize the extent of [32P]pApAp(8-azidoA) photoinsertion into the 80- and 37-kDa RNase L. In the absence of UV irradiation, there was no covalent cross-linking of the [32P]pApAp(8-azidoA) to RNase L. The amount of [32P]pApAp(8-azidoA) covalently bound to the 80- or 37-kDa RNase L was linear with respect to the amount of used PBMC extract or CFS PBMC extract up to 100 μg of total protein (data not shown). The best curve fit for the binding of the 2–5A azido photoprobe to the 80- and 37-kDa forms of RNase L following non-linear regression analysis was for a one-site model, which indicates that the molar ratio of 2–5A to RNase L is 1:1 (Fig. 1). Saturation of photolabeling by [32P]pApAp(8-azidoA) was approached at 3.0 × 10−7m for the 80- and 37-kDa RNase L (Fig. 1,B and D). Based on earlier photolabeling studies (23Dolan J.W. Marshall N.F. Richardson J.P. J. Biol. Chem. 1990; 265: 5747-5754Abstract Full Text PDF PubMed Google Scholar), we performed similar experiments assuming that the efficiency of 2–5A azido photolabeling of the 80- and 37-kDa is constant at all concentrations of [32P]pApAp(8-azidoA). These photolabeling data have been used to determine apparent dissociation constants, which are represented by the concentration at which 50% of the maximal photoinsertion is attained. The apparent meanKd for the 80-kDa RNase L in three healthy control PBMC extracts was determined to be 3.7 ± 2.8 × 10−8m. Half-maximal 2–5A azido photolabeling for the 80-kDa RNase L from the representative healthy control PBMC extract shown in Fig. 1 B is 6.9 × 10−8m. The apparent mean Kd for the 37-kDa RNase L in three CFS PBMC extracts was determined to be 6.3 ± 5.5 × 10−8m. Half-maximal 2–5A azido photolabeling for the 37-kDa RNase L from the representative CFS PBMC extract shown in Fig. 1 D is 1.7 × 10−7m. Saturation of photolabeling studies revealed relatively similar mean apparent Kd for the covalent binding of the [32P]pApAp(8-azidoA) to the 80- and 37-kDa RNase L. To determine the specificity of [32P]pApAp(8-azidoA) for the 2–5A-binding site on the 80- and 37-kDa RNase L, two types of competition experiments were completed using unlabeled pApAp(8-azidoA) or p3A3. In the first type, a concentration-dependent protection against photoaffinity labeling of the 80- and 37-kDa forms of RNase L was observed when healthy control and CFS PBMC extracts were incubated with a mixture of radiolabeled [32P]pApAp(8-azidoA) and unlabeled pApAp(8-azidoA), respectively (Fig. 2). The binding of the 2–5A photoaffinity probe to the 80-kDa RNase L was inhibited by 50% with 1.7 × 10−8munlabeled pApAp(8-azidoA) (Fig. 2, A and B, andB, inset), which is in good agreement with the apparent mean Kd determined from the saturation of photolabeling studies. Fifty percent protection against photoinsertion of [32P] pApAp(8-azidoA) into the 2–5A-binding site of the 37-kDa RNase L was achieved with 3.9 × 10−9m unlabeled pApAp(8-azidoA) (Fig. 2, C andD, and D, inset), which is consistent with the apparent mean Kd determined from the saturation of photolabeling experiments (Fig. 1). An apparent increase in covalent photoincorporation of [32P]pApAp(8-azidoA) into the 2–5A-binding site of the 80-kDa RNase L was observed when photolabeling mixtures contained unlabeled photoprobe at concentrations less than 1.0 × 10−8m (Fig. 2 B, inset). Such an apparent increase in photoincorporation can be observed only in the presence of unlabeled photoprobe at concentrations below the apparent Kd for ligand binding to a protein (24Trad C.H. Chavan A.J. Clemens J. Haley B.E. Arch. Biochem. Biophys. 1993; 304: 58-64Crossref PubMed Scopus (8) Google Scholar, 25Levitzki A. Koshland Jr., D.E. Biochemistry. 1972; 11: 247-252Crossref PubMed Scopus (80) Google Scholar). Under these conditions, a cooperative allosteric effect may occur, as has been demonstrated in isotope competition experiments with the photoprobe [α-32P]2-azido-NAD+ and ovine prolactin (24Trad C.H. Chavan A.J. Clemens J. Haley B.E. Arch. Biochem. Biophys. 1993; 304: 58-64Crossref PubMed Scopus (8) Google Scholar, 25Levitzki A. Koshland Jr., D.E. Biochemistry. 1972; 11: 247-252Crossref PubMed Scopus (80) Google Scholar). This precedent might account for the difference in requirements for formation of the activated complex for 80- and 37-kDa RNase L. Simultaneous incubation of 1.0 × 10−8m [32P]pApAp(8-azidoA) with unlabeled pApAp(8-azidoA) at concentrations less than 1.0 × 10−8m did not result in an increase in covalent photolabeling of [32P]pApAp(8-azidoA) to the 37-kDa RNase L (Fig. 2 D, inset). Incubation of a 100-fold excess of unlabeled pApAp(8-azidoA) (1.0 × 10−6m) with the 80-kDa RNase L resulted in complete inhibition of photolabeling (Fig. 2, B and B, inset). In contrast, complete inhibition of photolabeling of the 37-kDa RNase L was achieved by incubation with a 10-fold excess of unlabeled pApAp(8-azidoA) (1.0 × 10−7m) (Fig. 2, D and D, inset). Therefore, protection of photoinsertion by [32P]pApAp(8-azidoA) into the 80- and 37-kDa RNase L could be achieved with 100-fold excess unlabeled pApAp- (8-azidoA). Based on the data presented in Figs. 1 and 2, a second type of competition experiment was performed to measure the specific photolabeling of the 2–5A allosteric binding site of the 80- and 37-kDa forms of RNase L by [32P]pApAp(8-azidoA). Using authentic p3A3 at concentrations ranging from 1 × 10−11 to 1 × 10−6m in the presence of 1 × 10−8m[32P]pApAp(8-azidoA), a concentration-dependent protection of 2–5A azido photolabeling was observed (Fig. 3). Photoinsertion of [32P]pApAp(8-azidoA) into the 2–5A-binding site of the 80-kDa RNase L was inhibited 50% by p3A3 at a concentration of 7.6 × 10−10m (Fig. 3, A andC, ○), which is in agreement with 4 × 10−10m p3A4 required to inhibit 50% of the chemical cross-linking of 2–5A in L929 cell extracts (26Nolan-Sorden N.L. Lesiak K. Bayard B. Torrence P.F. Silverman R.H. Anal. Biochem. 1990; 184: 298-304Crossref PubMed Scopus (37) Google Scholar). Photolabeling of 37-kDa RNase L by [32P]pApAp(8-azidoA) was inhibited by 50% at a concentration of 1.2 × 10−10mp3A3 (Fig. 3, B and C, ●). Incubation of [32P]pApAp(8-azidoA) and p3A3 at equal concentrations (1 × 10−8m) with 80- and 37-kDa RNase L resulted in complete protection against covalent photolabeling (Fig.3 C). These data indicate that [32P]pApAp(8-azidoA) binds specifically to the 2–5A allosteric binding site of the 80- and 37-kDa RNase L. In contrast to the photoaffinity labeling/immunoprecipitation method used to determine 2–5A binding activity, the core(2–5A)-cellulose method is an affinity binding assay used to measure 2–5A-mediated hydrolysis of single-stranded RNA in the absence of non-2–5A-dependent RNases and other factors which may cause modifications, synthesis, or degradation of 2–5A (20Silverman R.H. Anal. Biochem. 1985; 144: 450-460Crossref PubMed Scopus (48) Google Scholar). We previously reported that RNase L activity as measured by the ribosomal RNA cleavage assay was elevated up to 45-fold in PBMC extracts from individuals with CFS compared with healthy controls (13Suhadolnik R.J. Reichenbach N.L. Hitzges P. Sobol R.W. Peterson D.L. Henry B. Ablashi D.V. Müller W.E.G. Schröder H.C. Carter W.A. Strayer D.R. Clin. Infect. Dis. 1994; 18: S96-S104Crossref PubMed Scopus (117) Google Scholar, 14Suhadolnik R.J. Reichenbach N.L. Hitzges P. Adelson M.E. Peterson D.L. Cheney P.R. Salvato P. Thompson C. Loveless M. Müller W.E.G. Schröder H.C. Strayer D.R. Carter W.A. In Vivo. 1994; 8: 599-604PubMed Google Scholar). In view of the elevated RNase L activity observed in CFS PBMC extracts, we hypothesized that, in the presence of 2–5A and poly(U)-3′-[32P]pCp, the 37-kDa RNase L would be more active than the 80-kDa RNase L. Time-dependent cleavage of poly(U)-3′-[32P]pCp by the 80- and 37-kDa forms of RNase L was observed (Fig. 4). Poly(C)-3′-[32P]pCp was also used to measure nonspecific RNase activity; the results revealed that the observed 2–5A-dependent RNase L activity was not due to the activity from nonspecific RNases (data not shown). Maximum hydrolysis of poly(U)-3′-[32P]pCp by the 80-kDa RNase L was attained at 60 min with half-maximal hydrolysis observed at 24 min (Fig.4 A). In PBMC extracts from healthy controls, we observed a maximum of 65% hydrolysis of poly(U)-3′-[32P]pCp at 120 min (Fig. 4 A), which is in reasonable agreement with the 80% hydrolysis observed in L929 cell extracts (20Silverman R.H. Anal. Biochem. 1985; 144: 450-460Crossref PubMed Scopus (48) Google Scholar). Only 2% hydrolysis of poly(U)-3′-[32P]pCp by the 80-kDa RNase L was observed at 10 min. The delay in the activation observed with the 80-kDa RNase L in healthy control PBMC extracts could be attributed to the time required for 80-kDa RNase L to dissociate from the core(2–5A)-cellulose and form its activated homodimer complex following the addition of poly(U)-3′-[32P]pCp and 2–5A. A similar lag time for the activation of 80-kDa RNase L immobilized on core(2–5A)-cellulose was previously observed for the 80-kDa RNase L in mouse L929 cell extracts (20Silverman R.H. Anal. Biochem. 1985; 144: 450-460Crossref PubMed Scopus (48) Google Scholar, 21Suhadolnik R.J. Kariko K. Sobol R.W. Li S.W. Reichenbach N.L. Haley B.E. Biochemistry. 1988; 27: 8840-8846Crossref PubMed Scopus (14) Google Scholar, 26Nolan-Sorden N.L. Lesiak K. Bayard B. Torrence P.F. Silverman R.H. Anal. Biochem. 1990; 184: 298-304Crossref PubMed Scopus (37) Google Scholar). In contrast, maximum hydrolysis of poly(U)-3′-[32P]pCp by the 37-kDa RNase L was attained by 30 min with half-maximal hydrolysis at 8 min (Fig. 4 B). Unlike the 80-kDa RNase L, the 37-kDa RNase L did not exhibit a lag time for activation. Taken together, these results strongly suggest that the 37-kDa RNase L hydrolyzes poly(U) at a rate three times faster than the 80-kDa RNase L. This increase in the hydrolysis of poly(U)-3′-[32P]pCp by the 37-kDa RNase L compares with a 10-fold increase in RNase L activity in CFS PBMC extracts as measured by ribosomal cleavage assays (13Suhadolnik R.J. Reichenbach N.L. Hitzges P. Sobol R.W. Peterson D.L. Henry B. Ablashi D.V. Müller W.E.G. Schröder H.C. Carter W.A. Strayer D.R. Clin. Infect. Dis. 1994; 18: S96-S104Crossref PubMed Scopus (117) Google Scholar, 14Suhadolnik R.J. Reichenbach N.L. Hitzges P. Adelson M.E. Peterson D.L. Cheney P.R. Salvato P. Thompson C. Loveless M. Müller W.E.G. Schröder H.C. Strayer D.R. Carter W.A. In Vivo. 1994; 8: 599-604PubMed Google Scholar). The aim of this study was to validate the specific interactions involved in the allosteric binding of 2–5A and activation of the 80- and 37-kDa forms of RNase L in PBMC extracts from healthy controls and individuals diagnosed with CFS, respectively. Further characterization of the molecular structure of the 37-kDa RNase L is underway in this laboratory (1Suhadolnik R.J. Peterson D.L. O'Brien K. Cheney P.R. Herst C.V.T. Reichenbach N.L. Kon N. Horvath S.E. Iacono K.T. Adelson M.E. De Meirleir K. De Becker P. Charubala R. Pfleiderer W. J. Interferon Cytokine Res. 1997; 17: 377-385Crossref PubMed Scopus (103) Google Scholar). The results in this study demonstrate that [32P]pApAp(8-azidoA) specifically binds to the 2–5A allosteric binding site of the 80- and 37-kDa RNase L with relatively the same affinity. However, time-dependent hydrolysis of poly(U)-3′-[32P]pCp was three times faster with the 37-kDa RNase L than with the 80-kDa RNase L, which suggests that the elevated RNase L activity observed in CFS PBMC extracts may be attributed to the increased affinity of the RNA substrate and to the increased efficiency of RNA cleavage the 37-kDa form of RNase L. Current efforts are aimed at extending these results to the identification of the amino acid sequence that comprises the 2–5A-binding site of the 37-kDa RNase L. Azido photoaffinity probes have been used to specifically identify ligand binding and active sites of enzymes (18Shoemaker M.T. Haley B.E. Biochemistry. 1993; 32: 1883-1890Crossref PubMed Scopus (39) Google Scholar, 27Kon N. Suhadolnik R.J. J. Biol. Chem. 1996; 271: 19983-19990Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar). Further examination of the parameters required for the formation of the activated complex for 37-kDa RNase L observed in CFS PBMC extracts is underway in this laboratory. The biochemical data presented in this study demonstrate the utility of [32P]pApAp(8-azidoA) for the detection of the 37-kDa RNase L. We thank Drs. Daniel L. Peterson, Kenney De Meirleir, and C. V. Herst for clinical evaluation of study subjects and providing PBMC from healthy controls and CFS patients. We also thank Dr. Wolfgang Pfleiderer for generously supplying the 2–5A azido photoaffinity probe, ApAp(8-azidoA), and 2–5A4, and Joseph W. Homan for preparing the core (2–5A)-cellulose. We especially thank Dr. David E. Ash and Dr. Barbara L. Stitt for critical review of the manuscript. Finally, we are thankful to Nancy L. Reichenbach for technical assistance and advice. Characterization of a 2′,5′-oligoadenylate (2-5A)-depen-dent 37-kDa RNase L. Azido photoaffinity labeling and 2-5A-dependent activation.Journal of Biological ChemistryVol. 276Issue 34PreviewPage 23707: The word “fatigue” was inadvertently omitted from line four of the abstract. The corrected sentence should read: “Up-regulation of key components of the 2′,5′-oligoadenylate (2-5A) synthetase/RNase L pathway has been identified in extracts of peripheral blood mononuclear cells from individuals with chronic fatigue syndrome, including the presence of a low molecular weight form of RNase L.” Full-Text PDF Open Access" @default.
W2022244154 created "2016-06-24" @default.
W2022244154 creator A5003434228 @default.
W2022244154 creator A5017043893 @default.
W2022244154 date "2001-06-01" @default.
W2022244154 modified "2023-10-18" @default.
W2022244154 title "Characterization of a 2′,5′-Oligoadenylate (2–5A)-dependent 37-kDa RNase L" @default.
W2022244154 cites W1558828789 @default.
W2022244154 cites W1567102080 @default.
W2022244154 cites W1587933079 @default.
W2022244154 cites W1964605210 @default.
W2022244154 cites W1964632864 @default.
W2022244154 cites W1986125715 @default.
W2022244154 cites W1987186067 @default.
W2022244154 cites W1992614295 @default.
W2022244154 cites W1999643385 @default.
W2022244154 cites W2007665536 @default.
W2022244154 cites W2009002447 @default.
W2022244154 cites W2012628524 @default.
W2022244154 cites W2029765186 @default.
W2022244154 cites W2032157300 @default.
W2022244154 cites W2035474345 @default.
W2022244154 cites W2086350134 @default.
W2022244154 cites W2098287790 @default.
W2022244154 cites W2100022997 @default.
W2022244154 cites W2103565638 @default.
W2022244154 cites W2114426595 @default.
W2022244154 cites W2118809707 @default.
W2022244154 cites W2120696122 @default.
W2022244154 cites W2138995305 @default.
W2022244154 cites W2252225016 @default.
W2022244154 cites W47210259 @default.
W2022244154 doi "https://doi.org/10.1074/jbc.m101243200" @default.
W2022244154 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11323422" @default.
W2022244154 hasPublicationYear "2001" @default.
W2022244154 type Work @default.
W2022244154 sameAs 2022244154 @default.
W2022244154 citedByCount "15" @default.
W2022244154 countsByYear W20222441542012 @default.
W2022244154 countsByYear W20222441542016 @default.
W2022244154 crossrefType "journal-article" @default.
W2022244154 hasAuthorship W2022244154A5003434228 @default.
W2022244154 hasAuthorship W2022244154A5017043893 @default.
W2022244154 hasBestOaLocation W20222441541 @default.
W2022244154 hasConcept C104317684 @default.
W2022244154 hasConcept C10879258 @default.
W2022244154 hasConcept C153911025 @default.
W2022244154 hasConcept C185592680 @default.
W2022244154 hasConcept C55493867 @default.
W2022244154 hasConcept C67705224 @default.
W2022244154 hasConcept C86803240 @default.
W2022244154 hasConceptScore W2022244154C104317684 @default.
W2022244154 hasConceptScore W2022244154C10879258 @default.
W2022244154 hasConceptScore W2022244154C153911025 @default.
W2022244154 hasConceptScore W2022244154C185592680 @default.
W2022244154 hasConceptScore W2022244154C55493867 @default.
W2022244154 hasConceptScore W2022244154C67705224 @default.
W2022244154 hasConceptScore W2022244154C86803240 @default.
W2022244154 hasIssue "26" @default.
W2022244154 hasLocation W20222441541 @default.
W2022244154 hasOpenAccess W2022244154 @default.
W2022244154 hasPrimaryLocation W20222441541 @default.
W2022244154 hasRelatedWork W1496120684 @default.
W2022244154 hasRelatedWork W1543738541 @default.
W2022244154 hasRelatedWork W1861872002 @default.
W2022244154 hasRelatedWork W1955165721 @default.
W2022244154 hasRelatedWork W1987454130 @default.
W2022244154 hasRelatedWork W2080557323 @default.
W2022244154 hasRelatedWork W2095046337 @default.
W2022244154 hasRelatedWork W2335930493 @default.
W2022244154 hasRelatedWork W3021329219 @default.
W2022244154 hasRelatedWork W611729512 @default.
W2022244154 hasVolume "276" @default.
W2022244154 isParatext "false" @default.
W2022244154 isRetracted "false" @default.
W2022244154 magId "2022244154" @default.
W2022244154 workType "article" @default.